Evidence map›Paper›PMID 41404609›Full record

ArticlebioRxiv : the preprint server for biology2025

Orthosteric Molecular Glue Inhibits COP9 Signalosome with Substrate-Dependent Potency.

Huigang Shi, Xiaorong Wang, Clinton Yu, Haibin Mao, Fenglong Jiao, Merav Braitbard, Ben Shor, Zhongsheng Zhang, Thomas R Hinds, Shiyun Cao and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Huigang ShiDepartment of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-2428-2500
Xiaorong WangDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.ORCID 0009-0007-6700-1277
Clinton YuDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.ORCID 0000-0002-2931-5474
Haibin MaoDepartment of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-7233-9105
Fenglong JiaoDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.ORCID 0000-0003-3399-5377
Merav BraitbardThe Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0002-6776-6612
Ben ShorThe Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0009-0003-8313-6842
Zhongsheng ZhangDepartment of Biochemistry, University of Washington, Seattle, WA 98175, USA.
Thomas R HindsDepartment of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0003-0581-4046
Shiyun CaoDepartment of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-1201-4963
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, WA 98175, USA.
Dina Schneidman-DuhovnyThe Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID 0000-0003-0480-0438
Lan HuangDepartment of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Ning ZhengDepartment of Pharmacology, Box 357280, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-1039-1581

Funding

Supplement: Advancing Proteomics Technologies to Decipher the Ubiquitin-Proteasome SystemR35GM145249 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lan Huang · 2022 to 2026
$3.2M
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas diseaseR01AI152358 · NIAID · UNIVERSITY OF WASHINGTON · PI BUCKNER, FREDERICK SIMMONS, FAN, ERKANG · 2020 to 2023
$3.1M
Structural surfaceomics to probe conformation-selective immunotherapy targetsR01CA290875 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lan Huang, Arun P. Wiita · 2024 to 2026
$2.7M
Development of dual effective kinase inhibitors as syndromic treatment of Giardiasis and CryptosporidiosisR01AI179768 · NIAID · UNIVERSITY OF WASHINGTON · PI Erkang Fan, Kayode K Ojo · 2024 to 2026
$2.3M
NCI NIH HHS R01 CA290875NIAID NIH HHS R01 AI152358NIAID NIH HHS R01 AI179768NIGMS NIH HHS R35 GM145249
6 · The paper itself

Abstract

Orthosteric inhibitors block enzyme active sites and prevent substrates from binding. Enhancing their specificity through substrate dependence seems inherently unlikely, as their mechanism hinges on direct competition rather than selective recognition. Here, we show that a molecular glue mechanism unexpectedly imparts substrate-dependent potency to CSN5i-3, an orthosteric inhibitor of the COP9 signalosome (CSN). We first confirm that CSN5i-3 inhibits CSN, which catalyzes NEDD8 deconjugation from the cullin-RING ubiquitin ligases (CRLs), by occupying the active site of its catalytic subunit, CSN5, and directly competing with the iso-peptide bond substrate. Curiously, the orthosteric inhibitor binds free CSN with only micromolar affinity, yet achieves nanomolar potency in blocking its deneddylase activity. Cryo-EM structures of the enzyme-substrate-inhibitor complex reveal that active site-engaged CSN5i-3 occludes the substrate iso-peptide linkage while simultaneously extending an NEDD8-binding exosite of CSN5, acting as a molecular glue to cement the NEDD8-CSN5 interaction. The cooperativity of this tri-molecular CSN5i-3-NEDD8-CSN5 assembly, in turn, sequesters CSN5i-3 at its binding site, conferring high potency to the orthosteric inhibitor despite its low affinity for the free enzyme. Together, our findings highlight the modest affinity requirements of molecule glues for individual target proteins and establish "orthosteric molecular glue inhibitors" as a new class of substrate-dependent enzyme antagonists.

Identifiers

PMID41404609
PMCPMC12703994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.